| Patent application number | Description | Published |
|---|
| 20100095873 | Method for pretreating charges contaminated with carbon carriers - In a method for pretreating charges contaminated with carbon carriers such as, for instance, carbon-carrier-contaminated earths, soils, rocks or minerals having low calorific values for use in clinker kilns, the mentioned charges are introduced into a reactor ( | 04-22-2010 |
| 20130152826 | Process for utilizing organic waste materials - In a process for utilizing organic waste materials, in particular cellulose-containing, moist, organic waste materials, in a clinker production process in which the waste materials are introduced as fuel and burnt in the clinker production process, the waste materials are brought into contact with the hot exhaust gases of the clinker production process and dried in a drying step flowing in parallel therewith before they are introduced into the clinker production process. The drying step is carried out in a drying reactor in which the moist waste materials are passed together with the hot exhaust gases through a series of concentrically arranged tubes, with multiple changes in flow direction about 180°, and the temperature of the hot exhaust gases is set to a maximum value of 400° C. by mixing in of ambient air and/or air from the clinker production process before the drying step. (FIG. | 06-20-2013 |
| Patent application number | Description | Published |
|---|
| 20100119489 | Stimulation of Pancreatic Beta Cell Proliferation - This invention provides a polypeptide, TMEM27, and secreted forms thereof, nucleic acids and constructs encoding the same, and cells comprising the same. The TMEM27 protein is expressed in hormone positive cells at early stages of pancreas development and pancreatic β-cells in the mature pancreas, whose expression promotes pancreatic β-cell replication and increased islet mass. Applications of the protein in diagnostics and therapeutics are described. | 05-13-2010 |
| 20120122959 | Targeting MicroRNAs for Metabolic Disorders - Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA. | 05-17-2012 |
| 20140113953 | Targeting MicroRNAs for Metabolic Disorders - Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA. | 04-24-2014 |
| 20150038550 | Targeting MicroRNAs for Metabolic Disorders - Provided herein are methods and compositions for the treatment of metabolic disorders. Also provided herein are methods and compositions for the reduction of blood glucose level, the reduction of gluceoneogenesis, the improvement of insulin resistance and the reduction of plasma cholesterol level. In certain embodiments, the methods comprise inhibiting the activity of miR-103. In certain embodiments, the methods comprise inhibiting the activity of miR-107. In certain embodiments, the activity of both miR-103 and miR-107 is inhibited. In certain embodiments, such methods comprise administering a compound comprising an oligonucleotide targeted to a microRNA. | 02-05-2015 |
| Patent application number | Description | Published |
|---|
| 20090043082 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 02-12-2009 |
| 20090275729 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 11-05-2009 |
| 20100003317 | COMPOSITIONS AND METHODS FOR MEDIATING RNAI IN VIVO - This invention relates to new formulated lipid particles (FLiPs) comprising at least one of a single or double stranded oligonucleotide, where the oligonucleotide has been conjugated to a lipophile and at least one of an emulsion or liposome to which the conjugated oligonucleotide has been aggregated, admixed or associated. These particles have surprisingly been shown to effectively deliver oligonucleotides to heart, lung and muscle where they effect gene silencing. | 01-07-2010 |
| 20100222413 | Chemically Modified Oligonucleotides for Use in Modulating Micro RNA and Uses Thereof - This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system. | 09-02-2010 |
| 20120077265 | MicroRNA and Methods for Inhibiting Same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 03-29-2012 |
| 20130130370 | MicroRNA and Methods for Inhibiting Same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 05-23-2013 |
| 20140073684 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES FOR USE IN MODULATING MICRO RNA AND USES THEREOF - This invention relates generally to chemically modified oligonucleotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonucleotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system. | 03-13-2014 |
| Patent application number | Description | Published |
|---|
| 20140287152 | PROCESS FOR THE PRODUCTION OF AN OEM BASE COAT/CLEAR TOP COAT MULTI-LAYER COATING - A process for the production of an OEM base coat/clear top coat multi-layer coating wherein a waterborne base coat composition is spray-applied by electrostatically-assisted high speed rotary atomization is provided. The waterborne base coat composition comprises binder solids comprising about 20 to about 100 wt. % of an aqueously dispersed polyurethane urea resin with a carboxyl number of 10 to 50 mg KOH/g | 09-25-2014 |
| 20140295091 | PROCESS FOR THE PRODUCTION OF AN AUTOMOTIVE OEM MULTI-LAYER COATING - A process for the production of an automotive OEM multi-layer coating, includes, but is not limited to applying a base coat layer onto an automotive substrate, applying a clear top coat layer onto the base coat layer, and jointly curing the base coat and clear top coat layers. The base coat layer is applied from a modified water-borne base coat produced by mixing an unmodified water-borne base coat with a polyisocyanate crosslinker component making use of a static mixer, and wherein the polyisocyanate crosslinker component comprises at least one polyisocyanate crosslinker and γ-butyrolactone as water-miscible solvent. | 10-02-2014 |
| 20140299021 | NON-AQUEOUS SOLVENT COMPOSITION AND ITS USE AS BARRIER LIQUID - A non-aqueous solvent composition comprising 0 to 10 wt. % of N-alkyl pyrrolidone, 0 to 5 wt. % of dimethyl sulfoxide, 10 to 50 wt. % of γ-butyrolactone, 10 to 50 wt. % of at least one monoalcohol, 10 to 60 wt. % of at least one organic solvent inert towards isocyanate groups, other than γ-butyrolactone, other than N-alkyl pyrrolidone, and consisting of carbon, hydrogen, oxygen and, optionally, nitrogen, and 0 to 10 wt. % of at least one additive. The non-aqueous solvent composition can be used as barrier liquid within a coating installation of an industrial mass production coating line for the application of water-borne two-component polyurethane coatings. | 10-09-2014 |
